Search

Your search keyword '"Mao, Feng"' showing total 105 results

Search Constraints

Start Over You searched for: Author "Mao, Feng" Remove constraint Author: "Mao, Feng" Publisher springer science and business media llc Remove constraint Publisher: springer science and business media llc
105 results on '"Mao, Feng"'

Search Results

7. Risk stratification of gallbladder masses by machine learning-based ultrasound radiomics models: a prospective and multi-institutional study

8. Syndecan-1 as an immunogene in Triple-negative breast cancer: regulation tumor-infiltrating lymphocyte in the tumor microenviroment and EMT by TGFb1/Smad pathway

9. Life expectancy and healthy life expectancy of patients with advanced schistosomiasis in Hunan Province, China

12. Long-term survival of screen-detected synchronous and metachronous bilateral non-palpable breast cancer among Chinese women: a hospital-based study (2003–2017)

15. Inequality of household water security follows a Development Kuznets Curve

21. Rationale and design of a phase II trial of pyrotinib in combination with nab-paclitaxel as adjuvant therapy for N0/N1mi, HER2 + early breast cancer (PHAEDRA)

23. Conductive and Transparent Properties of ZnO/Cu/ZnO Sandwich Structure

31. Do arbuscular mycorrhizal fungi help the native species Bidens biternata resist the invasion of Bidens alba?

36. Two-party quantum key agreement against collective noisy channel

37. Nanoscale redox mapping at the MoS2-liquid interface

40. Omitting radiotherapy is safe in breast cancer patients ≥ 70 years old after breast-conserving surgery without axillary lymph node operation

44. Fast growth of large-grain and continuous MoS2 films through a self-capping vapor-liquid-solid method

45. Pyrotinib with trastuzumab and aromatase inhibitors as first-line treatment for HER2 positive and hormone receptor positive metastatic or locally advanced breast cancer: study protocol of a randomized controlled trial

46. Breast-conserving surgery without axillary lymph node surgery or radiotherapy is safe for HER2-positive and triple negative breast cancer patients over 70 years of age

48. Validation of CTS5 model in large-scale breast cancer population and the impact of menopausal and HER2 status on its prognostic value

50. Targeting LRIG2 overcomes resistance to EGFR inhibitor in glioblastoma by modulating GAS6/AXL/SRC signaling

Catalog

Books, media, physical & digital resources